washington astrazeneca will file a request for approval of its novel coronavirus vaccine in the us later this year the pharmaceutical company said in a statement earlier this year concerns emerged over the side effects of the astrazeneca vaccine due to very rare cases of bloodclotting after vaccination after some nations temporarily suspended the use of the vaccine the world health organization who said it considers the benefits of the drug to outweigh its risks we continue to work with the fda us food and drug administration on submission the company said on wednesday currently the situation with respect to the pandemic and availability of alternative vaccine supply in the us doesnt really support an emergency use approval so we believe that us approval will be via a bla biologics license applications which we expect to be submitted later this year the fda has so far authorized three vaccines for emergency used across the united states in february 2021 the world health organization listed two versions of the astrazenecaoxford covid19 vaccine for emergency use giving the green light for these vaccines to be rolled out globally through the covax mechanism according to astrazeneca its vaccine shows 92 per cent and 86 per cent efficiency against hospitalization in the delta and alpha variant cases respectively at the same time a ukbased study from may published in the new england journal of medicine on july 21 showed that astrazeneca was 33 per cent effective after one dose 60 per cent effective after two